Mouse study could provide foundation for future human therapeutics
Supplementing a single protein found in the spinal cord could help prevent symptoms of Lou Gehrig’s disease, according to a new study out of Case Western Reserve University School of Medicine. Researchers found high levels of the protein—called mitofusion 2 or Mfn2—prevented nerve degeneration, muscle atrophy, and paralysis in a mouse model of the disease. Since Mfn2 is often depleted during Lou Gehrig’s, the new study suggests supplementing it could be a novel therapeutic approach for the disease.
Lou Gehrig’s disease, or amyloid lateral sclerosis (ALS), is a progressive disorder that devastates motor nerve cells. People with ALS slowly lose the ability to control muscle movement, and are ultimately unable to speak, eat, move, or breathe. The cellular mechanisms behind ALS are also found in certain types of dementia. For the estimated 15,000 Americans living with ALS, the findings offer new hope for ways to delay symptoms.
“We found a way to alleviate age and ALS-related muscular atrophy in our mouse models,” said Xinglong Wang, PhD, associate professor of pathology at Case Western Reserve University School of Medicine. “Amazingly, we could delay ALS symptom onset by 67 days.”
Wang led the study, recently published in Cell Metabolism, in which researchers successfully staved off muscle atrophy and paralysis simply by increasing Mfn2 levels in mouse spinal cords.
Wang and colleagues tested the most widely used ALS mouse model. They genetically engineered the diseased mice to have increased Mfn2 levels—but only in nerve cells that extend from the spinal cord and connect to muscle fibers. In late stages of the disease, mice with high Mfn2 levels in these nerves were a healthy weight, and did not have any of the muscle atrophy, gait abnormalities, or reduced grip strength that mice in control groups developed. Even mice who underwent heavy sciatic nerve damage benefited from elevated Mfn2 levels.
Said Wang, “Upregulation of Mfn2 specifically in nerve cells is sufficient to abolish skeletal muscle loss in ALS and aged mice, despite ALS-causing protein being found in all organs and tissues.”
By studying nerve cells collected from the mice, Wang’s team uncovered how Mfn2 offers its protective effects. The researchers found Mfn2 coexists with nutrients in cell structures called mitochondria. Their experiments showed mitochondria travel along nerve cell extensions—axons—and deliver the nutrients to the point where nerve cells and muscle fibers meet. This preserves sensitive connections—synapses—between nerve and muscle cells and prevents muscle atrophy. “We found mitochondria function as miniature ‘trucks’ to transport protein along axons to prevent synaptic degeneration,” explained Wang.
Cellular transport is not typically in the job description for mitochondria. The ancient cellular structures are well-known to be “powerhouses of the cell”—producing energy that keeps cells running. According to Wang, “this is a novel, previously unrecognized role for mitochondria.”
Specifically, Wang’s team found mitochondria use Mfn2 on their surfaces to carry a nutrient called calpstatin. Calpstatin inhibits harmful enzymes that break down nerves and muscle fibers. With the help of Mfn2, mitochondria carry calpstatin along nerve cells axons to meet muscle cells. There, calpstatin prevents enzymes from destroying delicate synapse connections. But without Mfn2, mitochondria can’t carry the nutrient.
According to Wang, the findings have broad implications. “Mfn2 deficiency or mutations are commonly observed in patients with ALS, peripheral neuropathy, Alzheimer’s disease, and other neurodegenerative diseases in which synaptic loss has long been recognized as a prominent early feature,” he says. “Supplementing Mfn2 may be a common and effective therapeutic approach to treat a wide range of diseases including but not limited muscular disorders, patients with nerve injury and various major neurodegenerative diseases associated with synaptic loss.”
The Latest on: Lou Gehrig’s Disease
via Google News
The Latest on: Lou Gehrig’s Disease
- Scientists from France, Uruguay, US Make Progress in ALS Treatment on October 5, 2018 at 7:46 pm
ALS is an incurable neuromuscular illness also known as Lou Gehrig’s disease. Gehrig (1903-1941), a hall-of-fame baseball player for the New York Yankees, was afflicted with ALS and forced to retire a... […]
- ALS drug approved by Health Canada could slow down progression of fatal disease on October 5, 2018 at 7:24 am
WATCH: Explaining ALS or Lou Gehrig’s disease ALS, also known as Lou Gehrig’s disease, gradually causes muscle weakness and disability because the brain progressively loses its capacity to ... […]
- Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease) treatment illuminated by new report on October 4, 2018 at 2:41 pm
This report focuses on the global Amyotrophic Lateral Sclerosis (Lou Gehrigs Disease) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to pre... […]
- Ottawa approves drug shown to slow down deadly neurological disease ALS on October 4, 2018 at 11:03 am
Canada is the fourth country to approve the drug, after Japan, South Korea and the U.S. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease also known as Lou Gehrig's disease. It eventu... […]
- Groundbreaking Cure HHT App for iOS, “My HHT Tracker”… on October 4, 2018 at 8:14 am
Those who are unaware they have HHT are at risks for dangerous complications. The disease is just as common as ALS, also called Lou Gehrig’s disease, but not as well known and difficult to diagnose. U... […]
- Groundbreaking Cure HHT App for iOS, "My HHT Tracker" Released for Rare Hereditary Disease on October 4, 2018 at 8:00 am
The disease is just as common as ALS, also called Lou Gehrig's disease, but not as well known and difficult to diagnose. Users of the new My HHT Tracker are able to track nosebleeds, test results ... […]
- Great reads on algal poison factories, American climate refugees, and more on October 4, 2018 at 7:51 am
The risks go way beyond dead dogs and sickened swimmers: Researchers recently found higher rates of liver disease and cancer in areas near blooms. Investigators in France, Florida and New England also ... […]
- Jeff Capel Jr.'s influence still felt through camp to benefit ALS research on October 4, 2018 at 4:32 am
Jeff Capel Jr. left a lasting impression on the Cape Fear region and beyond before losing his battle last November with amyotrophic lateral sclerosis, or Lou Gehrig's disease. But he is still making a... […]
- Battling ALS as a family on October 3, 2018 at 12:38 pm
Dr. Ayeez Lalji, was diagnosed with ALS (Lou Gehrig's Disease) in November of 2017. He currently owns 9 dental practices in the Greater Houston Area and is a self-made entrepreneur. ALS is extremely u... […]
via Bing News